Wall Street Zen lowered shares of Rallybio (NASDAQ:RLYB – Free Report) from a buy rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings downgraded Rallybio from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
View Our Latest Research Report on RLYB
Rallybio Price Performance
Rallybio’s stock is going to reverse split on the morning of Monday, November 23rd. The 1-2 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 19th.
Rallybio (NASDAQ:RLYB – Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($2.88) by $1.92. Rallybio had a negative return on equity of 31.44% and a negative net margin of 911.07%.
Rallybio Dividend Announcement
The company also recently declared a special dividend, which will be paid on Monday, November 30th. Investors of record on Thursday, November 5th will be issued a dividend of $13.56 per share. The ex-dividend date of this dividend is Monday, November 23rd.
Institutional Trading of Rallybio
A number of hedge funds have recently modified their holdings of the company. ADAR1 Capital Management LLC increased its position in Rallybio by 4,411.1% in the 2nd quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company’s stock valued at $14,822,000 after buying an additional 905,817 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Rallybio in the second quarter valued at approximately $1,155,000. BlackRock Inc. raised its stake in shares of Rallybio by 73.5% during the 2nd quarter. BlackRock Inc. now owns 30,332 shares of the company’s stock valued at $485,000 after purchasing an additional 12,846 shares during the period. Finally, State Street Corp purchased a new position in Rallybio during the second quarter valued at approximately $208,000. 90.34% of the stock is currently owned by institutional investors and hedge funds.
Rallybio Company Profile
Rallybio is a clinical-stage biotechnology company focused on developing treatments for people affected by rare and severe diseases. Founded in 2018, the company is based in New Haven, Connecticut, and has concentrated its research and development efforts on conditions with significant unmet medical needs. One of Rallybio’s investigational programs is RLYB212, an antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare condition that can cause dangerously low platelet counts in a fetus or newborn.
Recommended Stories
- Five stocks we like better than Rallybio
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
